Fundraising Fox
/Companies
Sign in

Latigo Bio

Thousand Oaks, US · 7 known investors

Find your way into Latigo Bio

Sign up to find every way you can get introduced to Latigo Bio

  • Your email: who you already know at Latigo Bio, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Latigo Bio team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk. The company aims to build a broad pipeline of pain therapeutics by leveraging its team's expertise in pain biology and clinical development.

BiotechHealthtechMedical Devices

Founders & leadership

NFNima Farzan
Nima FarzanExecutive
TLTim Lugo
Tim LugoExecutive
SH
Sean Harper Desmond PadhiFounder

Board

BSBeth Seidenberg
Beth SeidenbergBoard directorFounding Managing Director at Westlake Village BioPartners
JTJim Tananbaum
Jim TananbaumBoard directorFounder & CEO at Foresite Capital
DPDeborah Palestrant
Deborah PalestrantBoard directorPartner, Executive Chair, 4:59 Initiative at 5AM Ventures
KR
Kevin RaidyBoard director
NS
Nancy StaglianoBoard director
TW
Tim WalbertBoard director

Investors · 7

Access Biotechnologylisted by Access BiotechnologyNew York

How we know: Access Biotechnology's portfolio page · Not right? Tell us

Ascenta Capitallisted by Ascenta CapitalWilmington · $15M – $30M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Kern Capital, LLClisted by Kern Capital, LLCLarkspur · $5M – $15Mvia Jay Kern · inferred

How we know: Kern Capital, LLC's portfolio page · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Westlake Village BioPartnersreportedLos Angeles · $100K – $5Mvia Beth Seidenberg · board

How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Funding

SEC filings, press & company announcements

$395.6M disclosed across 2 rounds · 2025–2026

▶$50MraisedFeb 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nancy StaglianoDirector
  • Beth SeidenbergDirector
  • Nima FarzanExecutive Officer, Director
  • Jim TananbaumDirector
  • Deborah PalestrantDirector
  • Kevin RaidyDirector
  • Tim LugoExecutive Officer
  • Tim WalbertDirector
Offering amount
$150M
Amount sold
$50M
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Latigo Bio do?
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk. The company aims to build a broad pipeline of pain therapeutics by leveraging its team's expertise in pain biology and clinical development.
Who are Latigo Bio's investors?
Latigo Bio's investors include 5AM Ventures, Access Biotechnology, Ascenta Capital, Foresite Capital, Kern Capital, LLC, Sanofi Ventures, Westlake Village BioPartners.
How much funding has Latigo Bio raised?
Latigo Bio has disclosed $395.6M raised across 2 rounds.
Where is Latigo Bio headquartered?
Latigo Bio is headquartered in Thousand Oaks, US.